Improving DHA delivery in older adults at risk for dementia
Official title: Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia
Run by University of Cincinnati · NCT06933095 · Data updated 2026-11-12
This study is testing whether two different types of DHA supplements can improve brain health in older adults who are showing early signs of memory problems.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 55 Years to 82 Years |
| Sex | All |
| Enrollment | 153 (estimated) |
| Sponsor | University of Cincinnati Academic / other |
| Locations | 1 site (Cincinnati, Ohio) |
| Status | Recruiting |
| Started | September 15, 2024 |
| Main results expected | September 15, 2029 |
| Study ends | September 15, 2029 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT06933095 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men and women aged 62 to 80 who exhibit early signs of cognitive decline but do not have a diagnosis of significant neurological conditions.
✕Probably not a fit
Patients with diagnosed cognitive impairments such as Alzheimer's disease or other significant neurological disorders will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial aims to evaluate the effects of two different forms of DHA supplementation, LPC-DHA and TAG-DHA, on cerebrospinal fluid and blood DHA levels in elderly adults showing early signs of cognitive decline. Participants will receive either LPC-DHA or TAG-DHA capsules for 24 weeks, and the study will measure changes in neurodegenerative and neurotrophic biomarkers. The hypothesis is that LPC-DHA will be more effective than TAG-DHA in enhancing DHA levels and improving cognitive health markers.
Why it matters
Potential benefit: If successful, this study could lead to improved cognitive health and potentially delay the onset of dementia in at-risk elderly individuals.
How similar studies have gone: While there is existing evidence supporting the benefits of DHA supplementation, this specific comparison of LPC-DHA and TAG-DHA is a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. men and women 55 to 82 years old; 2. presence of subjective cognitive decline or mild cognitive decline using the SCD questionnaire, DEX, EMQ, MoCA; and mCDR; 3. No contraindication to a lumbar puncture (LP) unless opting to not have the LP (e.g., thrombocytopenia, coagulopathy, concomitant use of anticoagulant medications, etc.); 4. fluency in English; 5. ability to comprehend and comply with the research protocol; and 6. provision of written informed consent. Exclusion Criteria: 1. diagnosis of dementia due to AD, Parkinson's disease, frontotemporal dementia, multi-infarct dementia, head trauma with loss of consciousness lasting more than 5 minutes and resulting in persisting functional decline within the three years prior to enrollment, epilepsy, leukoencephalopathy, other neurological conditions that would interfere the study objectives, mMIST \<8 or MoCA-MI score \<7; 2. self-reported history of any psychotic disorder or bipolar disorder; 3. diagnosis of atrial fibrillation, pancreatic, liver, kidney or hematological coagulation disorder; 4. allergy to shellfish or seafood; 5. current substance use causing physiological dependence or persisting change in functional capability; 6. concomitant, regular use of medications that might affect primary outcome measures or adversely interact with the study product including anticoagulant medications; 7. weekly fish consumption more than 1 x 3 oz servings and/or use of DHA-containing supplements within 3 months prior to screening.
Where it's running
-
University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience
Cincinnati, Ohio, United States Recruiting
Study contacts
- Principal investigator: Robert McNamara, PhD — University of Cincinnati
- Study coordinator: Robert McNamara, PhD
- Email: mcnamar@ucmail.uc.edu
- Phone: 513-558-6831
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Can citicoline help prevent cognitive decline after delirium in older adults with hip fracture?
This study tests whether taking citicoline for 6 months after discharge helps prevent cognitive decline in adults 65 and older who had delirium during hospitalization for hip fracture.
-
See if cognitive impairment is common in older adults admitted for non-neurological rehab
This study tests how often cognitive impairment appears in patients aged 45 and older who are in non-neurological rehab units after hospitalization.
-
Effects of a Multidomain Community Program on Thinking and Quality of Life for Older Adults
This study tests whether a multidomain, community-based program can improve cognitive function and quality of life for adults aged 60 and up who are active participants at a center in Istanbul, Turkey.
-
Accelerated rTMS for Cognitive Function in adults with mild to moderate cognitive impairment
This study tests whether a short course of accelerated rTMS with the EXOMIND device can improve thinking skills in adults ages 50–90 with mild cognitive impairment or mild dementia.
-
Long-term walnut intake and brain function in abdominally obese adults
This trial tests whether eating walnuts for 24 weeks improves brain blood flow and insulin sensitivity, and whether it boosts thinking and appetite control in adults with abdominal obesity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.